LPath resumes dosing of iSONEP in the Phase II Nexus trial for wet AMD following lift of FDA clinical hold
LPath, Inc (OTCBB:LPTN, San Diego, USA), a lipid based antibody therapeutics company, has resumed dosing of their ocular formulation of the humanized monoclonal anti-S1P antibody,… Read More »LPath resumes dosing of iSONEP in the Phase II Nexus trial for wet AMD following lift of FDA clinical hold